Name: PAVMED INC (PAVM) Stock
Brand: PAVMED INC
Rating: 4.5 (3 reviews)

PAVM Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

5 days ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

19 days ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

24 days ago - By: Zacks Investment Research

PAVmed (PAVM) Upgraded to Strong Buy: Here's Why

a month ago - By: PAVmed Inc.

PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

6 months ago - By: Benzinga

PAVmed's Earnings: A Preview

2 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

2 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

2 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

2 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

2 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

2 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

3 months ago - By: The Motley Fool

PAVmed Revenue Jumps 513% in Q2

3 months ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

3 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

3 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

4 months ago - By: Lucid Diagnostics - Mentions: LUCD

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

4 months ago - By: PAVmed Inc.

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

5 months ago - By: Lucid Diagnostics - Mentions: LUCD

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

5 months ago - By: PAVmed Inc.

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

5 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

6 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

6 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

6 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

6 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

6 months ago - By: Zacks Investment Research